Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderat… (NCT06946511) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia
China50 participantsStarted 2025-08-01
Plain-language summary
This is a single-center, randomized, double-blind, placebo-controlled study. Patients will be randomly assigned to either the peptide intervention group (with dose escalation at 15mg, 30mg, 60mg, and 75mg) or the placebo control group. After learning and training, participants will receive an injection of PMS-001. The efficacy and safety of the intervention will be assessed at 1 hour, 1 day, 3 days, and 1 week post-intervention. This study aims to evaluate the effects of PMS-001 on improving long-delay recall in patients with moderate to severe dementia, as well as its safety profile.
Who can participate
Age range60 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participants must be aged 60 to 80 years (inclusive) at the time of screening, regardless of gender.
✓. Participants must have a Clinical Dementia Rating (CDR) total score \> 1, indicating moderate to severe dementia.
✓. Participants must provide written informed consent to participate in the study.
Exclusion criteria
✕. Presence of other neurological diseases that may cause cognitive decline, such as cerebrovascular disease, encephalitis, brain tumors, traumatic brain injury, epilepsy, Parkinson's disease, etc.
✕. Presence of metabolic diseases that may cause cognitive decline, such as anemia, thyroid dysfunction, folate and vitamin B12 deficiency, etc.
✕. Presence of severe psychiatric disorders, such as major depression.
✕. History of carbon monoxide poisoning.
✕. Presence of acute or severe life-threatening diseases.
✕. Presence of severe visual, auditory, or language impairments that would prevent the completion of neuropsychological assessments.
What they're measuring
1
To evaluate the efficacy of Peptide PMS-001 in improving long-delay recall in patients with moderate to severe dementia.
Timeframe: Clinical assessments will be conducted at baseline, and then at 1 hour, 1 day, 3 days, and 1 week after administration of the intervention.
✕. Current use of psychotropic medications or a history of substance abuse.
✕. Individuals with specific allergy histories, or those with a history of allergies to two or more medications, foods (such as milk), or pollen (excluding untreated, asymptomatic seasonal allergies), or known allergies to components of the study drug or similar agents.